trending Market Intelligence /marketintelligence/en/news-insights/trending/trms8cG9b5JaeV5Tgcqwvg2 content esgSubNav
In This List

Global Blood Therapeutics plans $100M common stock offering

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


Global Blood Therapeutics plans $100M common stock offering

Global Blood Therapeutics Inc. plans to sell $100 million of common stock in a registered underwritten public offering.

The company granted the underwriter an option to buy up to $15 million of its common stock.

Global Blood plans to use the net proceeds to fund the clinical development of voxelotor for treating sickle cell disease, and other clinical trials. It also intends to use the net proceeds for other research and development activities, working capital and general corporate purposes.

Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.